Cabazitaxel [CABA1]
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
- I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
- I confirm the patient has hormone-relapsed metastatic prostate cancer.
- I confirm the patient has received 225mg/m/sq or more of docetaxel and the disease has progressed during or after docetaxel chemotherapy.
- I confirm cabazitaxel is to be prescribed in combination with prednisone or prednisolone.
- I confirm the patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- I confirm the patient has been informed that treatment with cabazitaxel will be stopped if the disease progresses or after a maximum of 10 cycles (whichever happens first).
- I confirm the licensed dose and frequency of cabazitaxel will be used.
NHS funded From: 25 May 2016
Additional information
Current Form Version
Note
The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.